ArticleIEEE/ACM transactions on computational biology and bioinformatics
Outlier Analysis and Top Scoring Pair for Integrated Data Analysis and Biomarker Discovery.
Article in IEEE/ACM transactions on computational biology and bioinformatics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.Clinical epigenetics · 2017Trial
- OutSplice: A Novel Tool for the Identification of Tumor-Specific Alternative Splicing Events.BioMedInformatics · 2023Article
- Article
- Independent Drug Action in Combination Therapy: Implications for Precision Oncology.Cancer discovery · 2022Review
- Data analysis methods for defining biomarkers from omics data.Analytical and bioanalytical chemistry · 2022Review
- Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma.Epigenetics · 2020Article
- Functional characterization of alternatively spliced GSN in head and neck squamous cell carcinoma.Translational research : the journal of laboratory and clinical medicine · 2018Article
- Epigenetic regulation of gene expression in cancer: techniques, resources and analysis.Briefings in functional genomics · 2018Article
- A Novel Functional Splice Variant ofCancer research · 2017Article
- Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC.Oncotarget · 2017Article
- Toward Signaling-Driven Biomarkers Immune to Normal Tissue Contamination.Cancer informatics · 2016Article
- An argument for mechanism-based statistical inference in cancer.Human genetics · 2015Review
- Outlier Analysis Defines Zinc Finger Gene Family DNA Methylation in Tumors and Saliva of Head and Neck Cancer Patients.PloS one · 2015Article
- Correcting transcription factor gene sets for copy number and promoter methylation variations.Drug development research · 2014Article
- Learning dysregulated pathways in cancers from differential variability analysis.Cancer informatics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
Pathway deregulation has been identified as a key driver of carcinogenesis, with proteins in signaling pathways serving as primary targets for drug development. Deregulation can be driven by a number of molecular events, including gene mutation, epigenetic changes in gene promoters, overexpression, and gene amplifications or deletions. We demonstrate a novel approach that identifies pathways of interest by integrating outlier analysis within and across molecular data types with gene set analysis. We use the results to seed the top-scoring pair algorithm to identify robust biomarkers associated with pathway deregulation. We demonstrate this methodology on pediatric acute myeloid leukemia (AML) data. We develop a biomarker in primary AML tumors, demonstrate robustness with an independent primary tumor data set, and show that the identified biomarkers also function well in relapsed pediatric AML tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.